These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 20631300)

  • 1. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
    Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
    Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
    Anguille S; Van de Velde AL; Smits EL; Van Tendeloo VF; Juliusson G; Cools N; Nijs G; Stein B; Lion E; Van Driessche A; Vandenbosch I; Verlinden A; Gadisseur AP; Schroyens WA; Muylle L; Vermeulen K; Maes MB; Deiteren K; Malfait R; Gostick E; Lammens M; Couttenye MM; Jorens P; Goossens H; Price DA; Ladell K; Oka Y; Fujiki F; Oji Y; Sugiyama H; Berneman ZN
    Blood; 2017 Oct; 130(15):1713-1721. PubMed ID: 28830889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
    Maslak PG; Dao T; Krug LM; Chanel S; Korontsvit T; Zakhaleva V; Zhang R; Wolchok JD; Yuan J; Pinilla-Ibarz J; Berman E; Weiss M; Jurcic J; Frattini MG; Scheinberg DA
    Blood; 2010 Jul; 116(2):171-9. PubMed ID: 20400682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
    Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
    Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
    Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
    Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
    Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
    Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
    Front Immunol; 2020; 11():559152. PubMed ID: 33101274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
    Rezvani K; Yong AS; Mielke S; Savani BN; Musse L; Superata J; Jafarpour B; Boss C; Barrett AJ
    Blood; 2008 Jan; 111(1):236-42. PubMed ID: 17875804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
    Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
    Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the WT1
    Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
    Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
    Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
    Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
    Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
    J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
    Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
    Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
    Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
    J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.
    Keilholz U; Letsch A; Busse A; Asemissen AM; Bauer S; Blau IW; Hofmann WK; Uharek L; Thiel E; Scheibenbogen C
    Blood; 2009 Jun; 113(26):6541-8. PubMed ID: 19389880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
    Kuball J; de Boer K; Wagner E; Wattad M; Antunes E; Weeratna RD; Vicari AP; Lotz C; van Dorp S; Hol S; Greenberg PD; Heit W; Davis HL; Theobald M
    Cancer Immunol Immunother; 2011 Feb; 60(2):161-71. PubMed ID: 20963411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.